Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine

AIDS Research and Human Retroviruses

Volumn 12, Issue 11, 1996, Pages 977-983

  Krogstad, Paul ^a   Chen, Irvin S Y ^b   Canon, Jude ^a   Rey, Osvaldo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DNA SYNTHESIS; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029760428     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.977     Document Type: Article

References (25)

1. Lacey SF, Reardon JE, Furfine ES, Kunkel TA, Bebenek K, Eckert KA, Kemp SD, and Larder BA: Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 1992;267:15789-15794.
2. Busso M and Resnick L: Development of an assay that detects transcriptionally competent human immunodeficiency virus type one particles. J Virol Methods 1994;47:129-139.
3. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, and Chen ISY: Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987; 1236:819-822.
4. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol 1986;59: 284-291.
5. Zack JA, Haislip AM, Krogstad P, and Chen IS: Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-1725.
6. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, and Griffin J: Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-11245.
7. Yong WH, Wyman S, and Levy JA: Optimal conditions for synthesizing complementary DNA in the HIV-1 endogenous reverse transcriptase reaction. AIDS 1990;4:199-206.
8. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen IS: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61: 213-222.
9. Abbott MA, Poiesz BJ, Byrne BC, Kwok S, Sninsky JJ, and Ehrlich GD: Enzymatic gene amplification: Qualitative and quantitative methods for detecting proviral DNA amplified in vitro. J Infect Dis 1988;158:1158-1169.
10. Boone LR and Skalka A: Two species of full-length cDNA are synthesized in high yield by melittin-treated avian retrovirus particles. Proc Natl Acad Sci USA 1980;77:847-851.
11. Borroto-Esoto K and Boone LR: Development of a human immunodeficiency virus-1 in vitro DNA synthesis system to study reverse transcriptase inhibitors. Antiviral Res 1994;23:235-249.
12. Borroto-Esoto K and Boone LR: Equine infectious anemia virus and human immunodeficiency virus DNA synthesis in vitro: Charac-terization of the endogenous reverse transcriptase reaction. J Virol 1991;65:1952-1959.
13. Trono D: Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992;66: 4893-4900.
14. Lori F, di Marzo Veronese F, de Vico A, Lusso P, Reitz MJ, and Gallo RC: Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992;66:5067-5074.
15. Wainberg MA, Tremblay M, Rooke R, Blain N, Soudeyns H, Parniak MA, Yao XJ, Li XG, Fanning M, Montaner JS, et al.: Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study. Ann NY Acad Sci 1990;616:346-355.
16. Krogstad P and Chen ISY: Unpublished data.
17. Gilboa E, Mitra SW, Goff S, and Baltimore D: A detailed model of reverse transcription and tests of crucial aspects. Cell 1979;18: 93-100.
18. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
19. Bacolla A, Shih CK, Rose JM, Piras G, Warren TC, Grygon CA, Ingraham RH, Cousins RC, Greenwood DJ, Richman D, et al.: Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem 1993;268: 16571-16577.
20. Larder BA: Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994;75:951-957.
21. Richman D, Grimes JM, and Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 1990;3:743-746.
22. Fitzgibbon JE, Farnham AE, Sperber SJ, Kim H, and Dubin DT: Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol 1993;67:7271-7275.
23. Kaplan AH, Krogstad P, Kempf DJ, Norbeck DW, and Swanstrom R: Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA. Anitmicrob Agents Chemother 1994;38:2929-2933.
24. Martin JL, Wilson JE, Haynes RL, and Furman PA: Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc Natl Acad Sci USA 1993;90:6135-6139.
25. Spence R, Kati W, Anderson K, and Johnson K: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-993.